{"title":"中药治疗慢性肺部疾病的疗效和安全性：系统综述和荟萃分析。","authors":"Shan An, Hong-Yan Cai","doi":"10.3389/fmed.2025.1512729","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>To assess the efficacy and safety of various TCMIs treatments for COPD using network meta-analysis, providing evidence and guidance for clinical practice.</p><p><strong>Methods: </strong>We will search 7 databases for randomized controlled trials of TCMI for the COPD, including PubMed, the Cochrane Library, EMbase, China National Knowledge Infrastructure, China Biological Medicine, Chinese Scientific Journals Database, and Wan-fang databases, from the date of the establishment of each database to October 31, 2021. The network meta-analysis will be implemented through Aggregate Data Drug Information System 1.16.8 and Stata13.0 software. Pulmonary function included forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), and FEV1/FVC will be the primary outcomes, FEV1 as a percentage of the estimated value, maximal voluntary ventilation (MVV), MVV as a percentage of the estimated value, 6 min walking distance, The St.</p><p><strong>Results: </strong>A total of seven appropriate studies were identified, encompassing 490 patients. The quality of the literature was satisfactory, with no significant publication bias detected. The effectiveness rate for patients receiving a combination of TCM and Western Medicine (WM) compared to those on WM alone was evaluated as an odds ratio (OR), with statistical testing yielding <i>Z</i> = 6.09. For PO2 levels post-treatment, the mean difference (MD) was reported as 5.92.</p><p><strong>Conclusion: </strong>The results of this study will evaluate the efficacy and safety of TCMI in the treatment of COPD, and provide decision-making references for future clinical and scientific research.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/PROSPERO/view/CRD420251047046, identifier CRD420251047046.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1512729"},"PeriodicalIF":3.1000,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12162991/pdf/","citationCount":"0","resultStr":"{\"title\":\"Efficacy and safety of traditional Chinese medicine in the treatment of chronic pulmonary diseases: a systematic review and meta-analysis.\",\"authors\":\"Shan An, Hong-Yan Cai\",\"doi\":\"10.3389/fmed.2025.1512729\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>To assess the efficacy and safety of various TCMIs treatments for COPD using network meta-analysis, providing evidence and guidance for clinical practice.</p><p><strong>Methods: </strong>We will search 7 databases for randomized controlled trials of TCMI for the COPD, including PubMed, the Cochrane Library, EMbase, China National Knowledge Infrastructure, China Biological Medicine, Chinese Scientific Journals Database, and Wan-fang databases, from the date of the establishment of each database to October 31, 2021. The network meta-analysis will be implemented through Aggregate Data Drug Information System 1.16.8 and Stata13.0 software. Pulmonary function included forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), and FEV1/FVC will be the primary outcomes, FEV1 as a percentage of the estimated value, maximal voluntary ventilation (MVV), MVV as a percentage of the estimated value, 6 min walking distance, The St.</p><p><strong>Results: </strong>A total of seven appropriate studies were identified, encompassing 490 patients. The quality of the literature was satisfactory, with no significant publication bias detected. The effectiveness rate for patients receiving a combination of TCM and Western Medicine (WM) compared to those on WM alone was evaluated as an odds ratio (OR), with statistical testing yielding <i>Z</i> = 6.09. For PO2 levels post-treatment, the mean difference (MD) was reported as 5.92.</p><p><strong>Conclusion: </strong>The results of this study will evaluate the efficacy and safety of TCMI in the treatment of COPD, and provide decision-making references for future clinical and scientific research.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/PROSPERO/view/CRD420251047046, identifier CRD420251047046.</p>\",\"PeriodicalId\":12488,\"journal\":{\"name\":\"Frontiers in Medicine\",\"volume\":\"12 \",\"pages\":\"1512729\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-05-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12162991/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/fmed.2025.1512729\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fmed.2025.1512729","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
摘要
背景：通过网络荟萃分析，评价各种TCMIs治疗COPD的疗效和安全性，为临床实践提供依据和指导。方法：检索PubMed、Cochrane图书馆、EMbase、中国国家知识基础设施、中国生物医学、中国科学期刊数据库、万方数据库等7个数据库，从各数据库建立之日起至2021年10月31日，检索中药中药治疗COPD的随机对照试验。网络meta分析将通过Aggregate Data Drug Information System 1.16.8和Stata13.0软件进行。肺功能包括1秒用力呼气量（FEV1）、用力肺活量（FVC）和FEV1/FVC将是主要结局，FEV1占估计值的百分比、最大自主通气（MVV）、MVV占估计值的百分比、6分钟步行距离。结果：共确定了7项合适的研究，包括490例患者。文献质量令人满意，未发现明显的发表偏倚。采用优势比（OR）评价中西医结合治疗与单用中西医结合治疗的有效率，统计检验结果Z = 6.09。治疗后PO2水平的平均差异（MD）为5.92。结论：本研究结果将评价中药中药治疗慢性阻塞性肺病的疗效和安全性，为今后临床和科学研究提供决策参考。系统综述注册：https://www.crd.york.ac.uk/PROSPERO/view/CRD420251047046，标识符CRD420251047046。
Efficacy and safety of traditional Chinese medicine in the treatment of chronic pulmonary diseases: a systematic review and meta-analysis.
Background: To assess the efficacy and safety of various TCMIs treatments for COPD using network meta-analysis, providing evidence and guidance for clinical practice.
Methods: We will search 7 databases for randomized controlled trials of TCMI for the COPD, including PubMed, the Cochrane Library, EMbase, China National Knowledge Infrastructure, China Biological Medicine, Chinese Scientific Journals Database, and Wan-fang databases, from the date of the establishment of each database to October 31, 2021. The network meta-analysis will be implemented through Aggregate Data Drug Information System 1.16.8 and Stata13.0 software. Pulmonary function included forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), and FEV1/FVC will be the primary outcomes, FEV1 as a percentage of the estimated value, maximal voluntary ventilation (MVV), MVV as a percentage of the estimated value, 6 min walking distance, The St.
Results: A total of seven appropriate studies were identified, encompassing 490 patients. The quality of the literature was satisfactory, with no significant publication bias detected. The effectiveness rate for patients receiving a combination of TCM and Western Medicine (WM) compared to those on WM alone was evaluated as an odds ratio (OR), with statistical testing yielding Z = 6.09. For PO2 levels post-treatment, the mean difference (MD) was reported as 5.92.
Conclusion: The results of this study will evaluate the efficacy and safety of TCMI in the treatment of COPD, and provide decision-making references for future clinical and scientific research.
期刊介绍：
Frontiers in Medicine publishes rigorously peer-reviewed research linking basic research to clinical practice and patient care, as well as translating scientific advances into new therapies and diagnostic tools. Led by an outstanding Editorial Board of international experts, this multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care. In this spirit, the journal publishes the latest research results and medical knowledge that facilitate the translation of scientific advances into new therapies or diagnostic tools. The full listing of the Specialty Sections represented by Frontiers in Medicine is as listed below. As well as the established medical disciplines, Frontiers in Medicine is launching new sections that together will facilitate
- the use of patient-reported outcomes under real world conditions
- the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines
- the scientific bases for guidelines and decisions from regulatory authorities
- access to medicinal products and medical devices worldwide
- addressing the grand health challenges around the world
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
